Gabay Avraham sold $331K of ORMP
Gabay Avraham (Chief Financial Officer) sold 73,360 shares of ORAMED PHARMACEUTICALS INC. (ORMP) at $4.51 ($0.33M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale can marginally influence sentiment, but 10b5-1 pre-arrangement generally lowers the informational content versus discretionary selling.
Market read
A single CFO 10b5-1 sale (~$330.7K) is unlikely to drive a major repricing without additional corroborating news.
What to watch
The filing does not disclose reasons for sale; traders should watch for clustering of additional insider transactions or changes in trading patterns around the same window.
Background
The article is an SEC Form 4 insider transaction disclosure for ORMP, reporting an open-market sale by the CFO.
Ticker impact
ORMP CFO Gabay Avraham filed a Form 4 selling 73,360 shares on 2026-07-01 at $4.5085, totaling ~$330.7K.
Low likelihood of a sustained price move; any impact is likely short-lived unless follow-on selling accelerates.
The filing is primary-source and time-stamped, but the sale is explicitly under a pre-arranged 10b5-1 plan, reducing interpretive weight.
Market effects
Minimal; this is company-specific insider activity with no sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.
Key entities
- CompanyORMP
Oramed Pharmaceuticals Inc., issuer of the Form 4 insider transaction.
- InsiderGabay Avraham
Chief Financial Officer reporting the open-market sale.
- Trading mechanism10b5-1 plan
Pre-arranged plan that reduces interpretive weight of the sale.